Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Intellia Therapeutics, Inc. Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.	United States of America	NTLA
Intercure Ltd. Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.	Israel	INCR
Intercure Ltd. A leading producer of pharmaceutical-grade, GMP-certified medical cannabis products.	United States of America	INCR
Intervacc AB Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.	Sweden	IVACC
iNtRON Biotechnology, Inc. Develops phage therapeutics and molecular diagnostics to combat infectious diseases.	South Korea	048530
Inventage Lab Inc. Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.	South Korea	389470
Inventiva S.A. Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.	United States of America	IVA
Invivyd, Inc. Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.	United States of America	IVVD
IO Biotech, Inc. Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.	United States of America	IOBT
IONIS PHARMACEUTICALS INC A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.	United States of America	IONS